J 2021

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

BLANCHETTE, V. S., L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO et. al.

Basic information

Original name

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

Authors

BLANCHETTE, V. S. (guarantor), L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO, J. CURTIN, S. JACKSON, L. KHOO, Vladimir KOMRSKA (203 Czech Republic), D. LILLICRAP, M. MORFINI, Gabriela ROMANOVÁ (203 Czech Republic, belonging to the institution), D. STEPHENS, Ester ZAPOTOCKA (203 Czech Republic), M. L. RAND and Jan BLATNÝ (203 Czech Republic, belonging to the institution)

Edition

THROMBOSIS AND HAEMOSTASIS, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0340-6245

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 6.681

RIV identification code

RIV/00216224:14110/21:00121731

Organization unit

Faculty of Medicine

UT WoS

000640018700001

Keywords in English

factor VIII; hemophilia A; pharmacokinetic; observational study; population PK

Tags

International impact, Reviewed
Změněno: 25/2/2022 10:56, Mgr. Tereza Miškechová

Abstract

V originále

Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C]<2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24hours post home infusion of FVIII and then 3hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.